Chronic Pruritus in Atopic Patients Treated with Dupilumab: Real Life Response and Related Parameters in 354 Patients

被引:23
作者
Mastorino, Luca [1 ]
Rosset, Francois [1 ]
Gelato, Federica [1 ]
Ortoncelli, Michela [1 ]
Cavaliere, Giovanni [1 ]
Quaglino, Pietro [1 ]
Ribero, Simone [1 ]
机构
[1] Univ Turin, Dept Med Sci, Dermatol Clin, Via Cherasco 23, I-10121 Turin, Italy
关键词
pruritus; itching; dupilumab; atopic dermatitis; quality of life; ITCH; PATHOPHYSIOLOGY; DERMATITIS; DISEASE;
D O I
10.3390/ph15070883
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Chronic pruritus is a major symptom of atopic dermatitis (AD). Its etiopathogenesis is complex, and an understanding of the driving factors of its pathogenesis allows for the development of new molecule-targeted therapies. Dupilumab, targeting and blocking interleukin-4 (IL-4) and interleukin-13 (IL-13) molecules, has shown great efficacy in treating AD symptoms such chronic itching. We performed a retrospective observational study to evaluate possible chronic-itch-related characteristics and parameters in 356 AD patients who received dupilumab. The objective of the study was to evaluate the factors associated with the level of pruritus reported by patients at each of the 1575 detections in the form of the peak pruritus numerical rating scale (NRSpp) and sleep disturbance numerical rating scale (NRSsd). We focused on: the eczema area and severity index (EASI), dermatology life quality index (DLQI), patient-oriented eczema measure (POEMS), eosinophilia, L-lactate dehydrogenase (LDH), immunoglobulin E (IgE) and the time from the start of dupilumab therapy. NRSpp fell from 8.6 (sd 1.7) at baseline to 1.7 (sd 2.3) at 36 months and NRSsd from 7 (sd 3) to 0. Regarding the parameters that correlate with NRSpp, all the parameters analysed were significantly correlated except for eosinophils (p = 0.136). In the multivariate analysis, both considering and not considering treatment duration, the parameters were correlated (p < 0.001); EASI, DLQI, POEM, and LDH significantly correlated with NRSpp (p < 0.001 for each, except for LDH p = 0.003); while IgE tot lost significance (p = 0.337). Similar results were obtained for the parameters correlating with NRSsd. Our results confirm the efficacy of dupilumab on pruritus. The use of questionnaires such as DLQI and POEM is advisable in clinical practice and is adequate for assessing the impact of itching on AD. The low correlation of IgE and eosinophils, the ambiguity of LDH levels with the level of pruritus, and a poor clinical validity and unclear correlation with disease severity suggest a progressive abandonment of monitoring of these values.
引用
收藏
页数:9
相关论文
共 31 条
[1]   IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies [J].
Barrios, D. M. ;
Phillips, G. S. ;
Geisler, A. N. ;
Trelles, S. R. ;
Markova, A. ;
Noor, S. J. ;
Quigley, E. A. ;
Haliasos, H. C. ;
Moy, A. P. ;
Schram, A. M. ;
Bromberg, J. ;
Funt, S. A. ;
Voss, M. H. ;
Drilon, A. ;
Hellmann, M. D. ;
Comen, E. A. ;
Narala, S. ;
Patel, A. B. ;
Wetzel, M. ;
Jung, J. Y. ;
Leung, D. Y. M. ;
Lacouture, M. E. .
ANNALS OF ONCOLOGY, 2021, 32 (06) :736-745
[2]   Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis A Randomized Clinical Trial [J].
Blauvelt, Andrew ;
Teixeira, Henrique D. ;
Simpson, Eric L. ;
Costanzo, Antonio ;
De Bruin-Weller, Marjolein ;
Barbarot, Sebastien ;
Prajapati, Vimal H. ;
Lio, Peter ;
Hu, Xiaofei ;
Wu, Tianshuang ;
Liu, John ;
Ladizinski, Barry ;
Chu, Alvina D. ;
Eyerich, Kilian .
JAMA DERMATOLOGY, 2021, 157 (09) :1047-1055
[3]   Pathophysiology and therapy of pruritus in allergic and atopic diseases [J].
Buddenkotte, J. ;
Steinhoff, M. .
ALLERGY, 2010, 65 (07) :805-821
[4]   Pruritus as a Distinctive Feature of Type 2 Inflammation [J].
Garcovich, Simone ;
Maurelli, Martina ;
Gisondi, Paolo ;
Peris, Ketty ;
Yosipovitch, Gil ;
Girolomoni, Giampiero .
VACCINES, 2021, 9 (03)
[5]   Dupilumab: A review of its use in the treatment of atopic dermatitis [J].
Gooderham, Melinda J. ;
Hong, H. Chih-ho ;
Eshtiaghi, Panteha ;
Papp, Kim A. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 78 (03) :S28-S36
[6]   Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7) [J].
Gutermuth, J. ;
Pink, A. E. ;
Worm, M. ;
Soldbro, L. ;
Bjerregard Oland, C. ;
Weidinger, S. .
BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (03) :440-452
[7]   Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis A Phase 2b Randomized Clinical Trial [J].
Guttman-Yassky, Emma ;
Blauvelt, Andrew ;
Eichenfield, Lawrence F. ;
Paller, Amy S. ;
Armstrong, April W. ;
Drew, Janice ;
Gopalan, Ramanan ;
Simpson, Eric L. .
JAMA DERMATOLOGY, 2020, 156 (04) :411-420
[8]   Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus [J].
Kabashima, Kenji ;
Matsumura, Takayo ;
Komazaki, Hiroshi ;
Kawashima, Makoto .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (02) :141-150
[9]   Itch in Atopic Dermatitis [J].
Kido-Nakahara, Makiko ;
Furue, Masutaka ;
Ulzii, Dugarmaa ;
Nakahara, Takeshi .
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2017, 37 (01) :113-+
[10]   Dupilumab induces a rapid decrease of pruritus in adolescents: A pilot real-life study [J].
Mastorino, Luca ;
Viola, Riccardo ;
Panzone, Michele ;
Avallone, Gianluca ;
Gallo, Giuseppe ;
Ortoncelli, Michela ;
Cavaliere, Giovanni ;
Quaglino, Pietro ;
Ribero, Simone .
DERMATOLOGIC THERAPY, 2021, 34 (06)